5-bromo-1-isobutyl-3-methyl-6-[2-(trifluoromethyl)benzyl]-thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione | 372162-73-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 5-bromo-1-isobutyl-3-methyl-6-[2-(trifluoromethyl)benzyl]-thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
• 英文别名: 5-bromo-3-methyl-1-(2-methylpropyl)-6-[[2-(trifluoromethyl)phenyl]methyl]thieno[2,3-d]pyrimidine-2,4-dione
• CAS: 372162-73-7
• 化学式: C₁₉H₁₈BrF₃N₂O₂S
• 分子量: 475.329
• InChiKey: RXFCKHSZXVCAFR-UHFFFAOYSA-N

物化性质

• 沸点：
  515.0±60.0 °C(Predicted)
• 密度：
  1.481±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5.7
• 重原子数：
  28
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.37
• 拓扑面积：
  68.9
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  5-bromo-1-isobutyl-3-methyl-6-[2-(trifluoromethyl)benzyl]-thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione 在 草酰氯 、 异丙基氯化镁 、 N,N-二甲基甲酰胺 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 生成
  参考文献：
  名称：

  Potent blockers of the monocarboxylate transporter MCT1: Novel immunomodulatory compounds

  摘要：

  A novel series of potent blockers of the monocarboxylate transporter, MCT1, is disclosed. From very potent but lipophilic lead compounds, systematic changes to all parts of the molecule, targeting reduction in log D, afforded compounds with significantly improved overall properties. These Compounds show potent immunomodulatory activity. (C) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.01.024
• 作为产物：
  描述：

  5-Bromo-6-{hydroxy[2-(trifluoromethyl)phenyl]methyl]-1-isobutyl-3-methyl-thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione 在 三乙基硅烷 、 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 18.0h， 以84.5%的产率得到5-bromo-1-isobutyl-3-methyl-6-[2-(trifluoromethyl)benzyl]-thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
  参考文献：
  名称：

  Novel compounds

  摘要：

  这项发明提供了一般式1中的噻吩[2,3-d]嘧啶二酮，其中R、R1、R2和R3如规范中所定义，以及它们的生产工艺、含有它们的药物组合物以及它们在治疗中的用途。

  公开号：

  US20040122028A1

文献信息

• Thieno[2,3-d]pyrimidinediones and their use as pharmaceuticals
  申请人：——

  公开号：US20040014634A1

  公开（公告）日：2004-01-22

  The invention provides thieno[2,3-d]pyrimidinediones of general formula (I), wherein R, R 1 , R 2 and R 3 are as defined in the specification, processes for their production, pharmaceutical compositions containing them and their use in therapy. 1

  这项发明提供了通式（I）中的噻吩[2,3-d]嘧啶二酮，其中R、R1、R2和R3如规范中定义，其生产方法，含有它们的药物组合物以及它们在治疗中的用途。
• Thienopyrimidinediones and their use in the modulation of autoimmune disease
  申请人：——

  公开号：US20040254198A1

  公开（公告）日：2004-12-16

  The invention relates to a compound of formula (1); wherein: R 1 and R 2 each independently represent a C 1-6 alkyl, C 3-6 alkenyl, C 3-6 cycloalkyl C 1-3 alkyl or C 3-6 cycloalkyl; each of which may be optionally substituted by 1 to 3 halogen atoms; R 3 is isoxyzolidin-2-ylcarbonyl or tetrahydroisoxazin-2-ylcarbonyl wherein each ring is optionally substituted by one hydroxy group; Q is CO— or C(R 4 )(R 5 )—(wherein R 4 is a hydrogen atom or C 1-4 alkyl and R 5 is a hydrogen atom or hydroxy group); Ar is a 5- to 10-membered aromatic ring system wherein up to 4 ring atoms may be heteroatoms independently selected from nitrogen, oxygen and sulphur, the ring system being optionally substituted by one or more substituents as defined in the specification. It also relates to methods of preparing, pharmaceutical compositions containing and methods of using the compound of the formula (1), particularly in the modulation of autoimmune disease. 1

  本发明涉及一种式子(1)的化合物; 其中：R1和R2各自独立地表示C1-6烷基，C3-6烯基，C3-6环烷基，C1-3烷基或C3-6环烷基; 每个基团可能被1至3个卤素原子取代; R3是异噁唑啉-2-基甲酰基或四氢异噁唑啉-2-基甲酰基，其中每个环可能被一个羟基取代; Q是CO-或C（R4）（R5）-（其中R4是氢原子或C1-4烷基，R5是氢原子或羟基）; Ar是一个5-至10-成员的芳香环系统，其中最多4个环原子可以独立地选自氮，氧和硫，该环系统可能被一个或多个定义在说明书中的取代基取代。它还涉及制备，含有该式（1）化合物的制药组合物以及使用该化合物的方法，特别是在自身免疫性疾病的调节中使用。
• Chemical compounds
  申请人：——

  公开号：US20040171623A1

  公开（公告）日：2004-09-02

  The invention relates to a compound of formula (1)(A chemical formula should be inserted here—please see paper copy enclosed) wherein Q is —CO— or —C(R 4 )(R 5 )— (wherein R 4 is a hydrogen atom or C 1-4 alkyl and R 5 is a hydrogen atom or hydroxy group) and Ar is a 5- to 10-membered aromatic ring system wherein up to 4 ring atoms may be heteroatoms independently selected from nitrogen, oxygen and sulphur, the ring system being optionally substituted by one or more substituents as defined in the specification. It also relates to methods of preparing, pharmaceutical compositions containing and methods of using the compound of the formula (1), particularly in the modulation of autoimmune disease. 1

  本发明涉及一种式为（1）的化合物（化学式应在此处插入-请参见附上的纸质副本），其中Q为-CO-或-C（R4）（R5）-（其中R4为氢原子或C1-4烷基，R5为氢原子或羟基），Ar为一个5-至10-成员的芳香环系统，其中最多4个环原子可以是氮、氧和硫的杂原子，该环系统可以被定义在规范中的一种或多种取代基替换。本发明还涉及制备该式（1）化合物的方法，含有该化合物的药物组合物以及使用该化合物的方法，特别是在自身免疫性疾病的调节中。
• Compounds
  申请人：Ingall Anthony Howard

  公开号：US06890923B2

  公开（公告）日：2005-05-10

  A compound of formula or a pharmaceutically acceptable salt thereof, wherein R is —C(O)Ar 1 , —C(R 4 )(R 5 )Ar 1 or Ar 3 ; R 3 represents a group X—R 10 or Ar 2 ; X represents a bond or a group NR 11 ; and R 10 represents C 1-6 alkyl, C 2-6 alkenyl or C 2-6 alkynyl, each of which may be optionally substituted by one or more substituents independently selected from carboxyl, hydroxyl, —C(O)—R 12 , C 3-6 cycloalkyl, morpholinyl, —NR 13 R 14 , —SR 15 , —OR 16 , phenyl and halophenyl, or R 10 represents a C 3-6 cycloalkylcarbonyl, —C(O)CH 2 CN, halophenylcarbonyl or trifluoromethylcarbonyl group. The compounds or compositions thereof are useful in the treatment or prophylaxis of autoimmune, inflammatory, proliferative and hyperproliferative diseases.

  该化合物的分子式为或其药物可接受的盐，其中R为—C（O）Ar1，—C（R4）（R5）Ar1或Ar3；R3代表X—R10或Ar2基团；X代表键或NR11基团；R10代表C1-6烷基，C2-6烯基或C2-6炔基，每个基团都可以选择性地被一个或多个取代基独立地选自羧基，羟基，—C（O）—R12，C3-6环烷基，吗啉基，—NR13R14，—SR15，—OR16，苯基和卤代苯基，或R10代表C3-6环烷基羰基，—C（O）CH2CN，卤代苯基羰基或三氟甲基羰基基团。该化合物或其组成物在自身免疫性，炎症性，增生性和高增生性疾病的治疗或预防中有用。
• Chemical Compounds
  申请人：Reynolds Rachel Heulwen

  公开号：US20080153855A1

  公开（公告）日：2008-06-26

  The invention relates to a compound of formula (1) in which Q is —CO— or —C(R 4 )(R 5 )—, where R 4 is a hydrogen atom or C 1-4 alkyl and R 5 is a hydrogen atom or hydroxy group; and Ar is a 5- to 10-membered aromatic ring system where up to 4 ring atoms may be heteroatoms independently selected from nitrogen, oxygen and sulphur, the ring system being optionally substituted by one or more substituents as defined in the specification. It also relates to methods of preparing, pharmaceutical compositions containing and methods of using the compound of the formula (1), particularly in the modulation of autoimmune disease.

  本发明涉及一种化合物，其化学式为（1），其中Q为—CO—或—C（R4）（R5）—，其中R4为氢原子或C1-4烷基，R5为氢原子或羟基；Ar为一个5-到10-成员的芳香环系，其中最多4个环原子可以是氮、氧和硫的杂原子，该环系可以被定义在规范中的一个或多个取代基所取代。本发明还涉及制备方法、含有该化合物的药物组合物以及使用该化合物的方法，特别是在自身免疫性疾病的调节方面。